Successful treatment of MDR<i>Pseudomonas aeruginosa</i>skin and soft-tissue infection with ceftolozane/tazobactam: Table 1

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Joseph S. Solomkin, Ellie Hershberger, Benjamin Miller et al. · Clinical Infectious Diseases · 2015 · 410 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

Florian Wagenlehner, Obiamiwe Umeh, Judith N. Steenbergen et al. · The Lancet · 2015 · 382 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries

Mariana Castanheira, Lalitagauri M. Deshpande, Anthony Costello et al. · Journal of Antimicrobial Chemotherapy · 2014 · 210 citations

Life Sciences, Infectious Diseases, Pharmacology +17

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

Hélio S. Sader, Paul R. Rhomberg, David J. Farrell et al. · Antimicrobial Agents and Chemotherapy · 2011 · 123 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Prevalence of multidrug‐resistant pseudomonas aeruginosa and carbapenem‐resistant enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009

Marya D. Zilberberg, Andrew F. Shorr · Journal of Hospital Medicine · 2013 · 96 citations

Life Sciences, Infectious Diseases, Microbiology +17